PHAT Phathom Pharma Total Asset Value of Company
The linear price action on the Phathom Pharmaceuticals (PHAT) total assets chart on the GURU.Markets platform is 288.67, illustrating the position of this GI sector company. The business relies on a stable US domestic market with minimal geopolitical risks. Production is fully outsourced to external factories, creating a rigid dependency on vendors. Additionally, Phathom Pharmaceuticals (PHAT) delegates testing and global distribution to specialized contractors.
Analytical breakdowns and data insights for company Phathom Corp (PHAT)
Phathom Pharmaceuticals (PHAT) is transforming gastrointestinal therapy by developing innovative drugs for the treatment of esophagitis, a process that requires significant resource investments. An analysis of current gross assets, reverse-calculated via return on assets (ROA), reflects the aggregate of capital and liabilities; while steady growth in this metric confirms business expansion, purchasing at the peak of a trend risks severe portfolio corrections.